Investigating biomarkers in patients with lichen planus
Official title: Evaluation of the Clinical Specificity of Cellular and Molecular Biomarkers Identified in Patients With Lichen Planus
Run by Institut Pasteur · NCT06451744 · Data updated 2026-11-12
This study is trying to find specific immune cells in the blood of people with lichen planus to see if they are linked to HPV and can help improve diagnosis and understanding of the condition.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Institut Pasteur Industry-sponsored |
| Locations | 6 sites (Besançon and 5 other locations) |
| Status | Recruiting |
| Started | November 1, 2023 |
| Main results expected | April 30, 2026 |
| Study ends | April 30, 2027 |
| Registry record updated | July 1, 2025 |
| Trial ID | NCT06451744 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals newly diagnosed with lichen planus or experiencing a progressive episode of the disease without prior systemic treatment.
✕Probably not a fit
Patients with dermatosis localized exclusively in skin folds or on the face may not benefit due to the risk of scarring from biopsies.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on lichen planus, a chronic inflammatory condition affecting skin and mucous membranes, characterized by specific immune cell activity. It aims to identify unique T cell receptor (TCR) clonotypes associated with human papillomavirus (HPV) that may play a role in the disease's development. By collecting blood samples and performing biopsies, the study seeks to enhance the understanding of lichen planus and improve diagnostic accuracy. The research is particularly relevant for patients at the time of diagnosis or during disease progression.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods and targeted treatments for patients with lichen planus.
How similar studies have gone: Previous studies have identified TCR clonotypes in lichen planus, suggesting that this approach may yield valuable insights, although the specific methodology in this study is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject coming at the time of diagnosis of the disease before any systemic treatment, or at the time of a progressive episode of the disease, without systemic treatment or after cessation of immunomodulatory or immunosuppressive treatment * Ability to give their consent in writing * Must understand spoken and written French * Affiliated to the French social security or assimilated regimes Exclusion Criteria: * Dermatosis exclusively localised in the skin folds or on the face (risk of scarring from biopsies)
Where it's running
-
CHU de Besançon
Besançon, France Recruiting -
CHU Paris Seine-Saint-Denis- Hôpital Avicenne
Bobigny, France Recruiting -
Centre Medical de l'Institut Pasteur
Paris, France Recruiting -
Hôpital Saint-Louis
Paris, France Recruiting -
Hôpital Robert Debré, CHU de Reims
Reims, France Recruiting -
CHU de Rouen
Rouen, France Recruiting
Study contacts
- Principal investigator: Manuelle Vigiuer — CHU Reims Service de Dermatologie Avenue du Général Koenig 51092 Reims
- Study coordinator: Marie-Lise Gougeon
- Email: marie-lise.gougeon@pasteur.fr
- Phone: 1 40 66 97 87
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biomarkers that predict how skin-disease treatments will work
Researchers are testing blood and skin markers to see if they can forecast which patients with inflammatory skin diseases will respond to systemic treatments over a year.
-
Understanding the factors influencing chronic inflammatory skin diseases
This study is trying to understand what causes different types of chronic skin conditions, like eczema and psoriasis, to behave differently in patients over time.
-
MOPEVAC-Las vaccine in healthy adults to test safety and immune response for Lassa fever
A small study in healthy adults checks if MOPEVAC-Las is safe and can trigger an immune response, trying different dose levels.
-
Testing for viruses after a monkey bite
We will test adults who were recently bitten by a monkey or who have a history of monkey bites to see if they carry simian viruses such as STLV-1 or SFV using blood and saliva samples.
-
Speech therapy to improve lip-reading for people who use hearing aids
This will see if speech therapy for lip-reading improves visual speech recognition in adults with moderate-to-severe hearing loss who wear hearing aids.
-
How breast milk affects virus infectivity and transmission
This project will test whether components of donated breast milk change how viruses such as HTLV-1, Zika, dengue, yellow fever, and tick-borne encephalitis infect cells and could affect transmission.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.